Jean-François Korobelnik, Paolo Lanzetta, Charles C Wykoff, Tien Y Wong, Xin Zhang, Peter Morgan-Warren, Scott Fitzpatrick, Sergio Leal, Lynne Brunck, Zoran Hasanbasic, Karen W Chu, Kimberly Reed, Sobha Sivaprasad
{"title":"阿弗利百普(aflibercept)8 毫克可持续控制病情:视网膜新生血管疾病治疗的新基准。","authors":"Jean-François Korobelnik, Paolo Lanzetta, Charles C Wykoff, Tien Y Wong, Xin Zhang, Peter Morgan-Warren, Scott Fitzpatrick, Sergio Leal, Lynne Brunck, Zoran Hasanbasic, Karen W Chu, Kimberly Reed, Sobha Sivaprasad","doi":"10.1038/s41433-024-03312-w","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":12125,"journal":{"name":"Eye","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases.\",\"authors\":\"Jean-François Korobelnik, Paolo Lanzetta, Charles C Wykoff, Tien Y Wong, Xin Zhang, Peter Morgan-Warren, Scott Fitzpatrick, Sergio Leal, Lynne Brunck, Zoran Hasanbasic, Karen W Chu, Kimberly Reed, Sobha Sivaprasad\",\"doi\":\"10.1038/s41433-024-03312-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":12125,\"journal\":{\"name\":\"Eye\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Eye\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41433-024-03312-w\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03312-w","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
期刊介绍:
Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists.
Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.